You’re using a public version of DrugPatentWatch with free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 21, 2024

South Korea: These 45 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025

DrugPatentWatch® Estimated Loss of Exclusivity Dates in South Korea

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "South Korea: These 45 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025" DrugPatentWatch.com thinkBiotech, 2024 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can AEMCOLO (rifamycin) generic drug versions launch?

Generic name: rifamycin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 25, 2024
Generic Entry Controlled by: South Korea Patent 101,157,486

AEMCOLO is a drug marketed by Redhill. There are four patents protecting this drug.

This drug has twenty-eight patent family members in twenty-one countries.

See drug price trends for AEMCOLO.

The generic ingredient in AEMCOLO is rifamycin. There are eleven drug master file entries for this API. Additional details are available on the rifamycin profile page.

When can AEMCOLO (rifamycin) generic drug versions launch?

Generic name: rifamycin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 25, 2024
Generic Entry Controlled by: South Korea Patent 20,070,028,441
Patent Title: ORAL ANTIMICROBIAL PHARMACEUTICAL COMPOSITIONS

AEMCOLO is a drug marketed by Redhill. There are four patents protecting this drug.

This drug has twenty-eight patent family members in twenty-one countries.

See drug price trends for AEMCOLO.

The generic ingredient in AEMCOLO is rifamycin. There are eleven drug master file entries for this API. Additional details are available on the rifamycin profile page.

When can AEMCOLO (rifamycin) generic drug versions launch?

Generic name: rifamycin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 25, 2024
Generic Entry Controlled by: South Korea Patent 20,080,059,337
Patent Title: ORAL ANTIMICROBIAL PHARMACEUTICAL COMPOSITIONS

AEMCOLO is a drug marketed by Redhill. There are four patents protecting this drug.

This drug has twenty-eight patent family members in twenty-one countries.

See drug price trends for AEMCOLO.

The generic ingredient in AEMCOLO is rifamycin. There are eleven drug master file entries for this API. Additional details are available on the rifamycin profile page.

When can NUCYNTA (tapentadol hydrochloride) generic drug versions launch?

Generic name: tapentadol hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2024
Generic Entry Controlled by: South Korea Patent 101,096,501

Drug Price Trends for NUCYNTA
NUCYNTA is a drug marketed by Collegium Pharm Inc. There are four patents protecting this drug and four Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has forty-five patent family members in twenty-six countries. There has been litigation on patents covering NUCYNTA

See drug price trends for NUCYNTA.

The generic ingredient in NUCYNTA is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.

When can NUCYNTA (tapentadol hydrochloride) generic drug versions launch?

Generic name: tapentadol hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2024
Generic Entry Controlled by: South Korea Patent 20,070,039,929
Patent Title: CRYSTALLINE FORMS OF (-)-(1R,2R)-3-DIMETHYLAMINO-1-ETHYL-2-METHYLPROPYL)-PHENOL HYDROCHLORIDE

Drug Price Trends for NUCYNTA
NUCYNTA is a drug marketed by Collegium Pharm Inc. There are four patents protecting this drug and four Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has forty-five patent family members in twenty-six countries. There has been litigation on patents covering NUCYNTA

See drug price trends for NUCYNTA.

The generic ingredient in NUCYNTA is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.

When can NUCYNTA ER (tapentadol hydrochloride) generic drug versions launch?

Generic name: tapentadol hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2024
Generic Entry Controlled by: South Korea Patent 101,096,501

Drug Price Trends for NUCYNTA ER
NUCYNTA ER is a drug marketed by Collegium Pharm Inc. There are four patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and seventy-two patent family members in thirty-one countries. There has been litigation on patents covering NUCYNTA ER

See drug price trends for NUCYNTA ER.

The generic ingredient in NUCYNTA ER is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.

When can NUCYNTA ER (tapentadol hydrochloride) generic drug versions launch?

Generic name: tapentadol hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2024
Generic Entry Controlled by: South Korea Patent 20,070,039,929
Patent Title: CRYSTALLINE FORMS OF (-)-(1R,2R)-3-DIMETHYLAMINO-1-ETHYL-2-METHYLPROPYL)-PHENOL HYDROCHLORIDE

Drug Price Trends for NUCYNTA ER
NUCYNTA ER is a drug marketed by Collegium Pharm Inc. There are four patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and seventy-two patent family members in thirty-one countries. There has been litigation on patents covering NUCYNTA ER

See drug price trends for NUCYNTA ER.

The generic ingredient in NUCYNTA ER is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.

When can FYCOMPA (perampanel) generic drug versions launch?

Generic name: perampanel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 06, 2024
Generic Entry Controlled by: South Korea Patent 100,939,743

Drug Price Trends for FYCOMPA
FYCOMPA is a drug marketed by Catalyst Pharms. There are two patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has one hundred and one patent family members in thirty-three countries. There has been litigation on patents covering FYCOMPA

See drug price trends for FYCOMPA.

The generic ingredient in FYCOMPA is perampanel. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the perampanel profile page.

When can FYCOMPA (perampanel) generic drug versions launch?

Generic name: perampanel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 06, 2024
Generic Entry Controlled by: South Korea Patent 101,187,218

Drug Price Trends for FYCOMPA
FYCOMPA is a drug marketed by Catalyst Pharms. There are two patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has one hundred and one patent family members in thirty-three countries. There has been litigation on patents covering FYCOMPA

See drug price trends for FYCOMPA.

The generic ingredient in FYCOMPA is perampanel. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the perampanel profile page.

When can FYCOMPA (perampanel) generic drug versions launch?

Generic name: perampanel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 06, 2024
Generic Entry Controlled by: South Korea Patent 20,070,008,617
Patent Title: CRYSTAL OF 1,2-DIHYDROPYRIDINE COMPOUND AND METHOD FOR PRODUCING SAME

Drug Price Trends for FYCOMPA
FYCOMPA is a drug marketed by Catalyst Pharms. There are two patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has one hundred and one patent family members in thirty-three countries. There has been litigation on patents covering FYCOMPA

See drug price trends for FYCOMPA.

The generic ingredient in FYCOMPA is perampanel. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the perampanel profile page.

When can FYCOMPA (perampanel) generic drug versions launch?

Generic name: perampanel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 06, 2024
Generic Entry Controlled by: South Korea Patent 20,070,028,459
Patent Title: METHOD FOR PRODUCING 1,2-DIHYDROPYRIDINE-2-ONE COMPOUND

Drug Price Trends for FYCOMPA
FYCOMPA is a drug marketed by Catalyst Pharms. There are two patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has one hundred and one patent family members in thirty-three countries. There has been litigation on patents covering FYCOMPA

See drug price trends for FYCOMPA.

The generic ingredient in FYCOMPA is perampanel. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the perampanel profile page.

When can ERIVEDGE (vismodegib) generic drug versions launch?

Generic name: vismodegib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2024
Generic Entry Controlled by: South Korea Patent 101,225,018

ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.

This drug has fifty-four patent family members in twenty-four countries.

See drug price trends for ERIVEDGE.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.

When can ERIVEDGE (vismodegib) generic drug versions launch?

Generic name: vismodegib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2024
Generic Entry Controlled by: South Korea Patent 101,366,414

ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.

This drug has fifty-four patent family members in twenty-four countries.

See drug price trends for ERIVEDGE.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.

When can ERIVEDGE (vismodegib) generic drug versions launch?

Generic name: vismodegib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2024
Generic Entry Controlled by: South Korea Patent 20,070,085,243
Patent Title: PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING

ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.

This drug has fifty-four patent family members in twenty-four countries.

See drug price trends for ERIVEDGE.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.

When can ERIVEDGE (vismodegib) generic drug versions launch?

Generic name: vismodegib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2024
Generic Entry Controlled by: South Korea Patent 20,120,139,846
Patent Title: PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING

ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.

This drug has fifty-four patent family members in twenty-four countries.

See drug price trends for ERIVEDGE.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.

When can ERIVEDGE (vismodegib) generic drug versions launch?

Generic name: vismodegib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2024
Generic Entry Controlled by: South Korea Patent 20,130,083,488
Patent Title: PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING

ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.

This drug has fifty-four patent family members in twenty-four countries.

See drug price trends for ERIVEDGE.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.

When can ERIVEDGE (vismodegib) generic drug versions launch?

Generic name: vismodegib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2024
Generic Entry Controlled by: South Korea Patent 20,140,048,343
Patent Title: PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING

ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.

This drug has fifty-four patent family members in twenty-four countries.

See drug price trends for ERIVEDGE.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.

When can ERIVEDGE (vismodegib) generic drug versions launch?

Generic name: vismodegib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2024
Generic Entry Controlled by: South Korea Patent 20,150,002,863
Patent Title: PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING

ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.

This drug has fifty-four patent family members in twenty-four countries.

See drug price trends for ERIVEDGE.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.

When can ERIVEDGE (vismodegib) generic drug versions launch?

Generic name: vismodegib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2024
Generic Entry Controlled by: South Korea Patent 20,150,090,263
Patent Title: 헤지호그 신호전달에 대한 피리딜 억제제 (PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING)

ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.

This drug has fifty-four patent family members in twenty-four countries.

See drug price trends for ERIVEDGE.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.

When can ERIVEDGE (vismodegib) generic drug versions launch?

Generic name: vismodegib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2024
Generic Entry Controlled by: South Korea Patent 20,160,058,972
Patent Title: 헤지호그 신호전달에 대한 피리딜 억제제 (PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING)

ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.

This drug has fifty-four patent family members in twenty-four countries.

See drug price trends for ERIVEDGE.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.

When can ERIVEDGE (vismodegib) generic drug versions launch?

Generic name: vismodegib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2024
Generic Entry Controlled by: South Korea Patent 20,170,001,725
Patent Title: 헤지호그 신호전달에 대한 피리딜 억제제 (PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING)

ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.

This drug has fifty-four patent family members in twenty-four countries.

See drug price trends for ERIVEDGE.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.

When can ERIVEDGE (vismodegib) generic drug versions launch?

Generic name: vismodegib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2024
Generic Entry Controlled by: South Korea Patent 20,180,122,750
Patent Title: 헤지호그 신호전달에 대한 피리딜 억제제 (PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING)

ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.

This drug has fifty-four patent family members in twenty-four countries.

See drug price trends for ERIVEDGE.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.

When can ERIVEDGE (vismodegib) generic drug versions launch?

Generic name: vismodegib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2024
Generic Entry Controlled by: South Korea Patent 20,190,072,678
Patent Title: 헤지호그 신호전달에 대한 피리딜 억제제 (PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING)

ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.

This drug has fifty-four patent family members in twenty-four countries.

See drug price trends for ERIVEDGE.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.

When can ERIVEDGE (vismodegib) generic drug versions launch?

Generic name: vismodegib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2024
Generic Entry Controlled by: South Korea Patent 20,200,019,263
Patent Title: 헤지호그 신호전달에 대한 피리딜 억제제 (PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING)

ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.

This drug has fifty-four patent family members in twenty-four countries.

See drug price trends for ERIVEDGE.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.

When can ERIVEDGE (vismodegib) generic drug versions launch?

Generic name: vismodegib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2024
Generic Entry Controlled by: South Korea Patent 20,200,118,909
Patent Title: 헤지호그 신호전달에 대한 피리딜 억제제 (PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING)

ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.

This drug has fifty-four patent family members in twenty-four countries.

See drug price trends for ERIVEDGE.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.

When can ERIVEDGE (vismodegib) generic drug versions launch?

Generic name: vismodegib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2024
Generic Entry Controlled by: South Korea Patent 20,210,090,744
Patent Title: 헤지호그 신호전달에 대한 피리딜 억제제 (PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING)

ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.

This drug has fifty-four patent family members in twenty-four countries.

See drug price trends for ERIVEDGE.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.

When can SUSTOL (granisetron) generic drug versions launch?

Generic name: granisetron
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 28, 2024
Generic Entry Controlled by: South Korea Patent 20,070,083,851
Patent Title: SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS

SUSTOL is a drug marketed by Heron Theraps Inc. There are five patents protecting this drug.

This drug has eighteen patent family members in ten countries.

See drug price trends for SUSTOL.

The generic ingredient in SUSTOL is granisetron. There are twenty-six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the granisetron profile page.

When can QUARTETTE (ethinyl estradiol; levonorgestrel) generic drug versions launch?

Generic name: ethinyl estradiol; levonorgestrel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 07, 2024
Generic Entry Controlled by: South Korea Patent 20,090,094,437
Patent Title: METHODS OF HORMONAL TREATMENT UTILIZING ASCENDING-DOSE EXTENDED CYCLE REGIMENS

QUARTETTE is a drug marketed by Teva Branded Pharm. There are two patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.

This drug has twenty-three patent family members in thirteen countries. There has been litigation on patents covering QUARTETTE

See drug price trends for QUARTETTE.

The generic ingredient in QUARTETTE is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this API. Twenty-six suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.

When can INCIVEK (telaprevir) generic drug versions launch?

Generic name: telaprevir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 29, 2024
Generic Entry Controlled by: South Korea Patent 20,070,085,547
Patent Title: DOSE FORMS COMPRISING VX-950 AND THEIR DOSAGE REGIMEN

INCIVEK is a drug marketed by Vertex Pharms. There are two patents protecting this drug.

This drug has one hundred and twenty-four patent family members in thirty-eight countries.

The generic ingredient in INCIVEK is telaprevir. There are three drug master file entries for this API. Additional details are available on the telaprevir profile page.

When can INCIVEK (telaprevir) generic drug versions launch?

Generic name: telaprevir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 29, 2024
Generic Entry Controlled by: South Korea Patent 20,130,063,022
Patent Title: DOSE FORMS COMPRISING VX-950 AND THEIR DOSAGE REGIMEN

INCIVEK is a drug marketed by Vertex Pharms. There are two patents protecting this drug.

This drug has one hundred and twenty-four patent family members in thirty-eight countries.

The generic ingredient in INCIVEK is telaprevir. There are three drug master file entries for this API. Additional details are available on the telaprevir profile page.

When can YONDELIS (trabectedin) generic drug versions launch?

Generic name: trabectedin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 29, 2024
Generic Entry Controlled by: South Korea Patent 101,188,691

YONDELIS is a drug marketed by Janssen Prods. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has forty-four patent family members in thirty-six countries. There has been litigation on patents covering YONDELIS

See drug price trends for YONDELIS.

The generic ingredient in YONDELIS is trabectedin. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the trabectedin profile page.

When can YONDELIS (trabectedin) generic drug versions launch?

Generic name: trabectedin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 29, 2024
Generic Entry Controlled by: South Korea Patent 20,070,091,121
Patent Title: FORMULATIONS COMPRISING ECTEINASCIDIN AND A DISACCHARIDE

YONDELIS is a drug marketed by Janssen Prods. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has forty-four patent family members in thirty-six countries. There has been litigation on patents covering YONDELIS

See drug price trends for YONDELIS.

The generic ingredient in YONDELIS is trabectedin. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the trabectedin profile page.

When can HORIZANT (gabapentin enacarbil) generic drug versions launch?

Generic name: gabapentin enacarbil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 04, 2024
Generic Entry Controlled by: South Korea Patent 101,228,399

HORIZANT is a drug marketed by Azurity. There are five patents protecting this drug.

This drug has one hundred and forty-six patent family members in twenty-six countries.

See drug price trends for HORIZANT.

The generic ingredient in HORIZANT is gabapentin enacarbil. There are twenty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the gabapentin enacarbil profile page.

When can HORIZANT (gabapentin enacarbil) generic drug versions launch?

Generic name: gabapentin enacarbil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 04, 2024
Generic Entry Controlled by: South Korea Patent 20,070,074,604
Patent Title: GABAPENTIN PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS

HORIZANT is a drug marketed by Azurity. There are five patents protecting this drug.

This drug has one hundred and forty-six patent family members in twenty-six countries.

See drug price trends for HORIZANT.

The generic ingredient in HORIZANT is gabapentin enacarbil. There are twenty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the gabapentin enacarbil profile page.

When can KUVAN (sapropterin dihydrochloride) generic drug versions launch?

Generic name: sapropterin dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 17, 2024
Generic Entry Controlled by: South Korea Patent 20,070,084,270
Patent Title: STABLE TABLET FORMULATION

KUVAN is a drug marketed by Biomarin Pharm. There are ten patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and seventeen patent family members in twenty-six countries. There has been litigation on patents covering KUVAN

See drug price trends for KUVAN.

The generic ingredient in KUVAN is sapropterin dihydrochloride. There are three drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the sapropterin dihydrochloride profile page.

When can NEVANAC (nepafenac) generic drug versions launch?

Generic name: nepafenac
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 02, 2024
Generic Entry Controlled by: South Korea Patent 101,289,661

Drug Price Trends for NEVANAC
NEVANAC is a drug marketed by Harrow Eye. There are three patents protecting this drug.

This drug has twenty-seven patent family members in twenty-three countries.

See drug price trends for NEVANAC.

The generic ingredient in NEVANAC is nepafenac. There are eight drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the nepafenac profile page.

When can NEVANAC (nepafenac) generic drug versions launch?

Generic name: nepafenac
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 02, 2024
Generic Entry Controlled by: South Korea Patent 20,070,089,687
Patent Title: TOPICAL NEPAFENAC FORMULATIONS

Drug Price Trends for NEVANAC
NEVANAC is a drug marketed by Harrow Eye. There are three patents protecting this drug.

This drug has twenty-seven patent family members in twenty-three countries.

See drug price trends for NEVANAC.

The generic ingredient in NEVANAC is nepafenac. There are eight drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the nepafenac profile page.

When can DUTREBIS (lamivudine; raltegravir potassium) generic drug versions launch?

Generic name: lamivudine; raltegravir potassium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2024
Generic Entry Controlled by: South Korea Patent 101,350,420

DUTREBIS is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.

This drug has ninety-five patent family members in forty-three countries.

The generic ingredient in DUTREBIS is lamivudine; raltegravir potassium. There are twenty-nine drug master file entries for this API. Additional details are available on the lamivudine; raltegravir potassium profile page.

When can DUTREBIS (lamivudine; raltegravir potassium) generic drug versions launch?

Generic name: lamivudine; raltegravir potassium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2024
Generic Entry Controlled by: South Korea Patent 20,070,089,990
Patent Title: POTASSIUM SALT OF AN HIV INTEGRASE INHIBITOR

DUTREBIS is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.

This drug has ninety-five patent family members in forty-three countries.

The generic ingredient in DUTREBIS is lamivudine; raltegravir potassium. There are twenty-nine drug master file entries for this API. Additional details are available on the lamivudine; raltegravir potassium profile page.

When can DUTREBIS (lamivudine; raltegravir potassium) generic drug versions launch?

Generic name: lamivudine; raltegravir potassium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2024
Generic Entry Controlled by: South Korea Patent 20,130,122,031
Patent Title: POTASSIUM SALT OF AN HIV INTEGRASE INHIBITOR

DUTREBIS is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.

This drug has ninety-five patent family members in forty-three countries.

The generic ingredient in DUTREBIS is lamivudine; raltegravir potassium. There are twenty-nine drug master file entries for this API. Additional details are available on the lamivudine; raltegravir potassium profile page.

When can ISENTRESS (raltegravir potassium) generic drug versions launch?

Generic name: raltegravir potassium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2024
Generic Entry Controlled by: South Korea Patent 101,350,420

Drug Price Trends for ISENTRESS
ISENTRESS is a drug marketed by Msd Sub Merck. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-five patent family members in forty-five countries.

See drug price trends for ISENTRESS.

The generic ingredient in ISENTRESS is raltegravir potassium. There are five drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the raltegravir potassium profile page.

When can ISENTRESS (raltegravir potassium) generic drug versions launch?

Generic name: raltegravir potassium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2024
Generic Entry Controlled by: South Korea Patent 20,070,089,990
Patent Title: POTASSIUM SALT OF AN HIV INTEGRASE INHIBITOR

Drug Price Trends for ISENTRESS
ISENTRESS is a drug marketed by Msd Sub Merck. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-five patent family members in forty-five countries.

See drug price trends for ISENTRESS.

The generic ingredient in ISENTRESS is raltegravir potassium. There are five drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the raltegravir potassium profile page.

When can ISENTRESS (raltegravir potassium) generic drug versions launch?

Generic name: raltegravir potassium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2024
Generic Entry Controlled by: South Korea Patent 20,130,122,031
Patent Title: POTASSIUM SALT OF AN HIV INTEGRASE INHIBITOR

Drug Price Trends for ISENTRESS
ISENTRESS is a drug marketed by Msd Sub Merck. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-five patent family members in forty-five countries.

See drug price trends for ISENTRESS.

The generic ingredient in ISENTRESS is raltegravir potassium. There are five drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the raltegravir potassium profile page.

When can NEURACEQ (florbetaben f-18) generic drug versions launch?

Generic name: florbetaben f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 17, 2024
Generic Entry Controlled by: South Korea Patent 101,321,619

NEURACEQ is a drug marketed by Life Molecular. There is one patent protecting this drug.

This drug has thirty-five patent family members in twenty-seven countries.

The generic ingredient in NEURACEQ is florbetaben f-18. One supplier is listed for this generic product. Additional details are available on the florbetaben f-18 profile page.

When can NEURACEQ (florbetaben f-18) generic drug versions launch?

Generic name: florbetaben f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 17, 2024
Generic Entry Controlled by: South Korea Patent 20,070,093,427
Patent Title: STILBENE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES

NEURACEQ is a drug marketed by Life Molecular. There is one patent protecting this drug.

This drug has thirty-five patent family members in twenty-seven countries.

The generic ingredient in NEURACEQ is florbetaben f-18. One supplier is listed for this generic product. Additional details are available on the florbetaben f-18 profile page.

When can BELVIQ (lorcaserin hydrochloride) generic drug versions launch?

Generic name: lorcaserin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2024
Generic Entry Controlled by: South Korea Patent 101,281,919

Drug Price Trends for BELVIQ
BELVIQ is a drug marketed by One tentatively approved generic is ready to enter the market.

This drug has thirty-five patent family members in twenty-seven countries. There has been litigation on patents covering BELVIQ

See drug price trends for BELVIQ.

The generic ingredient in BELVIQ is lorcaserin hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the lorcaserin hydrochloride profile page.

When can BELVIQ (lorcaserin hydrochloride) generic drug versions launch?

Generic name: lorcaserin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2024
Generic Entry Controlled by: South Korea Patent 20,070,098,870
Patent Title: CRYSTALLINE FORMS OF (R)-8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE HYDROCHLORIDE

Drug Price Trends for BELVIQ
BELVIQ is a drug marketed by One tentatively approved generic is ready to enter the market.

This drug has thirty-five patent family members in twenty-seven countries. There has been litigation on patents covering BELVIQ

See drug price trends for BELVIQ.

The generic ingredient in BELVIQ is lorcaserin hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the lorcaserin hydrochloride profile page.

When can RECORLEV (levoketoconazole) generic drug versions launch?

Generic name: levoketoconazole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 10, 2025
Generic Entry Controlled by: South Korea Patent 101,387,910

RECORLEV is a drug marketed by Strongbridge. There are eight patents protecting this drug.

This drug has thirty-three patent family members in twenty-one countries.

See drug price trends for RECORLEV.

The generic ingredient in RECORLEV is levoketoconazole. One supplier is listed for this generic product. Additional details are available on the levoketoconazole profile page.

When can RECORLEV (levoketoconazole) generic drug versions launch?

Generic name: levoketoconazole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 10, 2025
Generic Entry Controlled by: South Korea Patent 20,070,100,781
Patent Title: METHODS AND COMPOSITIONS FOR TREATING DIABETES, METABOLIC SYNDROME AND OTHER CONDITIONS

RECORLEV is a drug marketed by Strongbridge. There are eight patents protecting this drug.

This drug has thirty-three patent family members in twenty-one countries.

See drug price trends for RECORLEV.

The generic ingredient in RECORLEV is levoketoconazole. One supplier is listed for this generic product. Additional details are available on the levoketoconazole profile page.

When can RECORLEV (levoketoconazole) generic drug versions launch?

Generic name: levoketoconazole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 10, 2025
Generic Entry Controlled by: South Korea Patent 20,140,030,327
Patent Title: METHODS AND COMPOSITIONS FOR TREATING DIABETES, METABOLIC SYNDROME AND OTHER CONDITION

RECORLEV is a drug marketed by Strongbridge. There are eight patents protecting this drug.

This drug has thirty-three patent family members in twenty-one countries.

See drug price trends for RECORLEV.

The generic ingredient in RECORLEV is levoketoconazole. One supplier is listed for this generic product. Additional details are available on the levoketoconazole profile page.

When can BELRAPZO (bendamustine hydrochloride) generic drug versions launch?

Generic name: bendamustine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 14, 2025
Generic Entry Controlled by: South Korea Patent 101,648,495

BELRAPZO is a drug marketed by Eagle Pharms. There are nine patents protecting this drug. Six tentatively approved generics are ready to enter the market.

This drug has sixty-four patent family members in thirty countries.

See drug price trends for BELRAPZO.

The generic ingredient in BELRAPZO is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.

When can BELRAPZO (bendamustine hydrochloride) generic drug versions launch?

Generic name: bendamustine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 14, 2025
Generic Entry Controlled by: South Korea Patent 101,918,188

BELRAPZO is a drug marketed by Eagle Pharms. There are nine patents protecting this drug. Six tentatively approved generics are ready to enter the market.

This drug has sixty-four patent family members in thirty countries.

See drug price trends for BELRAPZO.

The generic ingredient in BELRAPZO is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.

When can BELRAPZO (bendamustine hydrochloride) generic drug versions launch?

Generic name: bendamustine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 14, 2025
Generic Entry Controlled by: South Korea Patent 20,070,094,848
Patent Title: BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS FOR LYOPHILISATION

BELRAPZO is a drug marketed by Eagle Pharms. There are nine patents protecting this drug. Six tentatively approved generics are ready to enter the market.

This drug has sixty-four patent family members in thirty countries.

See drug price trends for BELRAPZO.

The generic ingredient in BELRAPZO is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.

When can BELRAPZO (bendamustine hydrochloride) generic drug versions launch?

Generic name: bendamustine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 14, 2025
Generic Entry Controlled by: South Korea Patent 20,160,098,530
Patent Title: 동결건조를 위한 벤다무스틴 약학 조성물 (BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS FOR LYOPHILISATION)

BELRAPZO is a drug marketed by Eagle Pharms. There are nine patents protecting this drug. Six tentatively approved generics are ready to enter the market.

This drug has sixty-four patent family members in thirty countries.

See drug price trends for BELRAPZO.

The generic ingredient in BELRAPZO is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.

When can BELRAPZO (bendamustine hydrochloride) generic drug versions launch?

Generic name: bendamustine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 14, 2025
Generic Entry Controlled by: South Korea Patent 20,170,096,221
Patent Title: 동결건조를 위한 벤다무스틴 약학 조성물 (BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS FOR LYOPHILISATION)

BELRAPZO is a drug marketed by Eagle Pharms. There are nine patents protecting this drug. Six tentatively approved generics are ready to enter the market.

This drug has sixty-four patent family members in thirty countries.

See drug price trends for BELRAPZO.

The generic ingredient in BELRAPZO is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.

When can BELRAPZO (bendamustine hydrochloride) generic drug versions launch?

Generic name: bendamustine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 14, 2025
Generic Entry Controlled by: South Korea Patent 20,180,056,804
Patent Title: 동결건조를 위한 벤다무스틴 약학 조성물 (BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS FOR LYOPHILISATION)

BELRAPZO is a drug marketed by Eagle Pharms. There are nine patents protecting this drug. Six tentatively approved generics are ready to enter the market.

This drug has sixty-four patent family members in thirty countries.

See drug price trends for BELRAPZO.

The generic ingredient in BELRAPZO is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.

When can BENDEKA (bendamustine hydrochloride) generic drug versions launch?

Generic name: bendamustine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 14, 2025
Generic Entry Controlled by: South Korea Patent 101,648,495

BENDEKA is a drug marketed by Eagle Pharms. There are eighteen patents protecting this drug and one Paragraph IV challenge. Six tentatively approved generics are ready to enter the market.

This drug has one hundred and twenty patent family members in thirty-one countries. There has been litigation on patents covering BENDEKA

See drug price trends for BENDEKA.

The generic ingredient in BENDEKA is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.

When can BENDEKA (bendamustine hydrochloride) generic drug versions launch?

Generic name: bendamustine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 14, 2025
Generic Entry Controlled by: South Korea Patent 101,918,188

BENDEKA is a drug marketed by Eagle Pharms. There are eighteen patents protecting this drug and one Paragraph IV challenge. Six tentatively approved generics are ready to enter the market.

This drug has one hundred and twenty patent family members in thirty-one countries. There has been litigation on patents covering BENDEKA

See drug price trends for BENDEKA.

The generic ingredient in BENDEKA is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.

When can BENDEKA (bendamustine hydrochloride) generic drug versions launch?

Generic name: bendamustine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 14, 2025
Generic Entry Controlled by: South Korea Patent 20,070,094,848
Patent Title: BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS FOR LYOPHILISATION

BENDEKA is a drug marketed by Eagle Pharms. There are eighteen patents protecting this drug and one Paragraph IV challenge. Six tentatively approved generics are ready to enter the market.

This drug has one hundred and twenty patent family members in thirty-one countries. There has been litigation on patents covering BENDEKA

See drug price trends for BENDEKA.

The generic ingredient in BENDEKA is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.

When can BENDEKA (bendamustine hydrochloride) generic drug versions launch?

Generic name: bendamustine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 14, 2025
Generic Entry Controlled by: South Korea Patent 20,160,098,530
Patent Title: 동결건조를 위한 벤다무스틴 약학 조성물 (BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS FOR LYOPHILISATION)

BENDEKA is a drug marketed by Eagle Pharms. There are eighteen patents protecting this drug and one Paragraph IV challenge. Six tentatively approved generics are ready to enter the market.

This drug has one hundred and twenty patent family members in thirty-one countries. There has been litigation on patents covering BENDEKA

See drug price trends for BENDEKA.

The generic ingredient in BENDEKA is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.

When can BENDEKA (bendamustine hydrochloride) generic drug versions launch?

Generic name: bendamustine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 14, 2025
Generic Entry Controlled by: South Korea Patent 20,170,096,221
Patent Title: 동결건조를 위한 벤다무스틴 약학 조성물 (BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS FOR LYOPHILISATION)

BENDEKA is a drug marketed by Eagle Pharms. There are eighteen patents protecting this drug and one Paragraph IV challenge. Six tentatively approved generics are ready to enter the market.

This drug has one hundred and twenty patent family members in thirty-one countries. There has been litigation on patents covering BENDEKA

See drug price trends for BENDEKA.

The generic ingredient in BENDEKA is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.

When can BENDEKA (bendamustine hydrochloride) generic drug versions launch?

Generic name: bendamustine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 14, 2025
Generic Entry Controlled by: South Korea Patent 20,180,056,804
Patent Title: 동결건조를 위한 벤다무스틴 약학 조성물 (BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS FOR LYOPHILISATION)

BENDEKA is a drug marketed by Eagle Pharms. There are eighteen patents protecting this drug and one Paragraph IV challenge. Six tentatively approved generics are ready to enter the market.

This drug has one hundred and twenty patent family members in thirty-one countries. There has been litigation on patents covering BENDEKA

See drug price trends for BENDEKA.

The generic ingredient in BENDEKA is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.

When can OTREXUP (methotrexate) generic drug versions launch?

Generic name: methotrexate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 24, 2025
Generic Entry Controlled by: South Korea Patent 20,070,117,543
Patent Title: PREFILLED NEEDLE ASSISTED JET INJECTOR

Drug Price Trends for OTREXUP
OTREXUP is a drug marketed by Otter Pharms. There are fourteen patents protecting this drug.

This drug has thirty-seven patent family members in fourteen countries. There has been litigation on patents covering OTREXUP

See drug price trends for OTREXUP.

The generic ingredient in OTREXUP is methotrexate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the methotrexate profile page.

When can WAKIX (pitolisant hydrochloride) generic drug versions launch?

Generic name: pitolisant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 10, 2025
Generic Entry Controlled by: South Korea Patent 101,344,271

WAKIX is a drug marketed by Harmony. There are three patents protecting this drug.

This drug has sixty-one patent family members in thirty-one countries. There has been litigation on patents covering WAKIX

See drug price trends for WAKIX.

The generic ingredient in WAKIX is pitolisant hydrochloride. One supplier is listed for this generic product. Additional details are available on the pitolisant hydrochloride profile page.

When can WAKIX (pitolisant hydrochloride) generic drug versions launch?

Generic name: pitolisant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 10, 2025
Generic Entry Controlled by: South Korea Patent 20,070,101,381
Patent Title: MONOHYDROCHLORIDE SALT OF 1-[3-[3-(4-CHLOROPHENYL)PROPOXY]PROPYL]-PIPERIDINE

WAKIX is a drug marketed by Harmony. There are three patents protecting this drug.

This drug has sixty-one patent family members in thirty-one countries. There has been litigation on patents covering WAKIX

See drug price trends for WAKIX.

The generic ingredient in WAKIX is pitolisant hydrochloride. One supplier is listed for this generic product. Additional details are available on the pitolisant hydrochloride profile page.

When can EUCRISA (crisaborole) generic drug versions launch?

Generic name: crisaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: South Korea Patent 101,337,045

Drug Price Trends for EUCRISA
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA

See drug price trends for EUCRISA.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.

When can EUCRISA (crisaborole) generic drug versions launch?

Generic name: crisaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: South Korea Patent 101,337,068

Drug Price Trends for EUCRISA
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA

See drug price trends for EUCRISA.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.

When can EUCRISA (crisaborole) generic drug versions launch?

Generic name: crisaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: South Korea Patent 101,426,220

Drug Price Trends for EUCRISA
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA

See drug price trends for EUCRISA.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.

When can EUCRISA (crisaborole) generic drug versions launch?

Generic name: crisaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: South Korea Patent 101,456,815

Drug Price Trends for EUCRISA
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA

See drug price trends for EUCRISA.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.

When can EUCRISA (crisaborole) generic drug versions launch?

Generic name: crisaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: South Korea Patent 20,070,112,390
Patent Title: BORON-CONTAINING SMALL MOLECULES

Drug Price Trends for EUCRISA
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA

See drug price trends for EUCRISA.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.

When can EUCRISA (crisaborole) generic drug versions launch?

Generic name: crisaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: South Korea Patent 20,080,110,984
Patent Title: BORON-CONTAINING SMALL MOLECULES

Drug Price Trends for EUCRISA
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA

See drug price trends for EUCRISA.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.

When can EUCRISA (crisaborole) generic drug versions launch?

Generic name: crisaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: South Korea Patent 20,100,105,869
Patent Title: BORON-CONTAINING SMALL MOLECULES

Drug Price Trends for EUCRISA
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA

See drug price trends for EUCRISA.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.

When can EUCRISA (crisaborole) generic drug versions launch?

Generic name: crisaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: South Korea Patent 20,130,095,330
Patent Title: BORON-CONTAINING SMALL MOLECULES

Drug Price Trends for EUCRISA
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA

See drug price trends for EUCRISA.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.

When can EUCRISA (crisaborole) generic drug versions launch?

Generic name: crisaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: South Korea Patent 20,130,100,019
Patent Title: BORON-CONTAINING SMALL MOLECULES

Drug Price Trends for EUCRISA
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA

See drug price trends for EUCRISA.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.

When can KERYDIN (tavaborole) generic drug versions launch?

Generic name: tavaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: South Korea Patent 101,337,045

Drug Price Trends for KERYDIN
KERYDIN is a drug marketed by Anacor Pharms Inc.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN

See drug price trends for KERYDIN.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.

When can KERYDIN (tavaborole) generic drug versions launch?

Generic name: tavaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: South Korea Patent 101,337,068

Drug Price Trends for KERYDIN
KERYDIN is a drug marketed by Anacor Pharms Inc.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN

See drug price trends for KERYDIN.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.

When can KERYDIN (tavaborole) generic drug versions launch?

Generic name: tavaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: South Korea Patent 101,426,220

Drug Price Trends for KERYDIN
KERYDIN is a drug marketed by Anacor Pharms Inc.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN

See drug price trends for KERYDIN.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.

When can KERYDIN (tavaborole) generic drug versions launch?

Generic name: tavaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: South Korea Patent 101,456,815

Drug Price Trends for KERYDIN
KERYDIN is a drug marketed by Anacor Pharms Inc.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN

See drug price trends for KERYDIN.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.

When can KERYDIN (tavaborole) generic drug versions launch?

Generic name: tavaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: South Korea Patent 20,070,112,390
Patent Title: BORON-CONTAINING SMALL MOLECULES

Drug Price Trends for KERYDIN
KERYDIN is a drug marketed by Anacor Pharms Inc.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN

See drug price trends for KERYDIN.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.

When can KERYDIN (tavaborole) generic drug versions launch?

Generic name: tavaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: South Korea Patent 20,080,110,984
Patent Title: BORON-CONTAINING SMALL MOLECULES

Drug Price Trends for KERYDIN
KERYDIN is a drug marketed by Anacor Pharms Inc.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN

See drug price trends for KERYDIN.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.

When can KERYDIN (tavaborole) generic drug versions launch?

Generic name: tavaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: South Korea Patent 20,100,105,869
Patent Title: BORON-CONTAINING SMALL MOLECULES

Drug Price Trends for KERYDIN
KERYDIN is a drug marketed by Anacor Pharms Inc.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN

See drug price trends for KERYDIN.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.

When can KERYDIN (tavaborole) generic drug versions launch?

Generic name: tavaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: South Korea Patent 20,130,095,330
Patent Title: BORON-CONTAINING SMALL MOLECULES

Drug Price Trends for KERYDIN
KERYDIN is a drug marketed by Anacor Pharms Inc.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN

See drug price trends for KERYDIN.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.

When can KERYDIN (tavaborole) generic drug versions launch?

Generic name: tavaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: South Korea Patent 20,130,100,019
Patent Title: BORON-CONTAINING SMALL MOLECULES

Drug Price Trends for KERYDIN
KERYDIN is a drug marketed by Anacor Pharms Inc.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN

See drug price trends for KERYDIN.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.

When can VOCABRIA (cabotegravir sodium) generic drug versions launch?

Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: South Korea Patent 101,363,875

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-five patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

When can VOCABRIA (cabotegravir sodium) generic drug versions launch?

Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: South Korea Patent 101,504,998

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-five patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

When can VOCABRIA (cabotegravir sodium) generic drug versions launch?

Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: South Korea Patent 101,580,310

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-five patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

When can VOCABRIA (cabotegravir sodium) generic drug versions launch?

Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: South Korea Patent 101,848,819

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-five patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

When can VOCABRIA (cabotegravir sodium) generic drug versions launch?

Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: South Korea Patent 20,080,009,733
Patent Title: POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-five patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

When can VOCABRIA (cabotegravir sodium) generic drug versions launch?

Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: South Korea Patent 20,080,064,182
Patent Title: POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON HIV INTEGRASE

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-five patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

When can VOCABRIA (cabotegravir sodium) generic drug versions launch?

Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: South Korea Patent 20,130,133,061
Patent Title: POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-five patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

When can VOCABRIA (cabotegravir sodium) generic drug versions launch?

Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: South Korea Patent 20,140,097,438
Patent Title: POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-five patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

When can VOCABRIA (cabotegravir sodium) generic drug versions launch?

Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: South Korea Patent 20,160,003,889
Patent Title: HIV 통합효소 억제 활성을 가지는 다환식 카르바모일피리돈 유도체 (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY)

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-five patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

When can CORLANOR (ivabradine) generic drug versions launch?

Generic name: ivabradine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: South Korea Patent 100,835,447

Drug Price Trends for CORLANOR
CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR

See drug price trends for CORLANOR.

The generic ingredient in CORLANOR is ivabradine. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine profile page.

When can CORLANOR (ivabradine) generic drug versions launch?

Generic name: ivabradine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: South Korea Patent 20,060,095,499
Patent Title: gamma;-CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE, A PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT

Drug Price Trends for CORLANOR
CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR

See drug price trends for CORLANOR.

The generic ingredient in CORLANOR is ivabradine. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine profile page.

When can CORLANOR (ivabradine hydrochloride) generic drug versions launch?

Generic name: ivabradine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: South Korea Patent 100,827,502

Drug Price Trends for CORLANOR
CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR

See drug price trends for CORLANOR.

The generic ingredient in CORLANOR is ivabradine hydrochloride. There are nine drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the ivabradine hydrochloride profile page.

When can CORLANOR (ivabradine hydrochloride) generic drug versions launch?

Generic name: ivabradine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: South Korea Patent 20,060,095,501
Patent Title: beta;-CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE, A PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT

Drug Price Trends for CORLANOR
CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR

See drug price trends for CORLANOR.

The generic ingredient in CORLANOR is ivabradine hydrochloride. There are nine drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the ivabradine hydrochloride profile page.

When can XIFAXAN (rifaximin) generic drug versions launch?

Generic name: rifaximin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 03, 2025
Generic Entry Controlled by: South Korea Patent 100,885,755

Drug Price Trends for XIFAXAN
XIFAXAN is a drug marketed by Salix Pharms. There are twenty-nine patents protecting this drug and two Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has two hundred and thirteen patent family members in forty countries. There has been litigation on patents covering XIFAXAN

See drug price trends for XIFAXAN.

The generic ingredient in XIFAXAN is rifaximin. There are fourteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rifaximin profile page.

When can XIFAXAN (rifaximin) generic drug versions launch?

Generic name: rifaximin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 03, 2025
Generic Entry Controlled by: South Korea Patent 20,060,096,242
Patent Title: NEW POLYMORPHOUS FORMS OF RIFAXIMIN, PROCESSES FOR THEIR PRODUCTION AND USE THEREOF IN MEDICINAL PREPARATIONS

Drug Price Trends for XIFAXAN
XIFAXAN is a drug marketed by Salix Pharms. There are twenty-nine patents protecting this drug and two Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has two hundred and thirteen patent family members in forty countries. There has been litigation on patents covering XIFAXAN

See drug price trends for XIFAXAN.

The generic ingredient in XIFAXAN is rifaximin. There are fourteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rifaximin profile page.

When can NEXAVAR (sorafenib tosylate) generic drug versions launch?

Generic name: sorafenib tosylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 07, 2025
Generic Entry Controlled by: South Korea Patent 101,335,932

NEXAVAR is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-nine patent family members in thirty-nine countries. There has been litigation on patents covering NEXAVAR

See drug price trends for NEXAVAR.

The generic ingredient in NEXAVAR is sorafenib tosylate. There are thirteen drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the sorafenib tosylate profile page.

When can NEXAVAR (sorafenib tosylate) generic drug versions launch?

Generic name: sorafenib tosylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 07, 2025
Generic Entry Controlled by: South Korea Patent 20,070,111,513
Patent Title: PHARMACEUTICAL COMPOSITION COMPRISING AN OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREA FOR THE TREATMENT OF CANCER

NEXAVAR is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-nine patent family members in thirty-nine countries. There has been litigation on patents covering NEXAVAR

See drug price trends for NEXAVAR.

The generic ingredient in NEXAVAR is sorafenib tosylate. There are thirteen drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the sorafenib tosylate profile page.

When can VALCHLOR (mechlorethamine hydrochloride) generic drug versions launch?

Generic name: mechlorethamine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 14, 2025
Generic Entry Controlled by: South Korea Patent 101,168,252

VALCHLOR is a drug marketed by Helsinn. There are six patents protecting this drug.

This drug has fifty patent family members in twenty countries.

See drug price trends for VALCHLOR.

The generic ingredient in VALCHLOR is mechlorethamine hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the mechlorethamine hydrochloride profile page.

When can VALCHLOR (mechlorethamine hydrochloride) generic drug versions launch?

Generic name: mechlorethamine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 14, 2025
Generic Entry Controlled by: South Korea Patent 20,070,120,163
Patent Title: STABILIZED COMPOSITIONS OF VOLATILE ALKYLATING AGENTS AND METHODS OF USING THEREOF

VALCHLOR is a drug marketed by Helsinn. There are six patents protecting this drug.

This drug has fifty patent family members in twenty countries.

See drug price trends for VALCHLOR.

The generic ingredient in VALCHLOR is mechlorethamine hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the mechlorethamine hydrochloride profile page.

When can OZEMPIC (semaglutide) generic drug versions launch?

Generic name: semaglutide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 18, 2025
Generic Entry Controlled by: South Korea Patent 101,205,272

Drug Price Trends for OZEMPIC
OZEMPIC is a drug marketed by Novo. There are twenty-one patents protecting this drug.

This drug has two hundred and twenty-six patent family members in twenty-eight countries. There has been litigation on patents covering OZEMPIC

See drug price trends for OZEMPIC.

The generic ingredient in OZEMPIC is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.

When can OZEMPIC (semaglutide) generic drug versions launch?

Generic name: semaglutide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 18, 2025
Generic Entry Controlled by: South Korea Patent 20,070,120,089
Patent Title: ACYLATED GLP-1 COMPOUNDS

Drug Price Trends for OZEMPIC
OZEMPIC is a drug marketed by Novo. There are twenty-one patents protecting this drug.

This drug has two hundred and twenty-six patent family members in twenty-eight countries. There has been litigation on patents covering OZEMPIC

See drug price trends for OZEMPIC.

The generic ingredient in OZEMPIC is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.

When can WEGOVY (semaglutide) generic drug versions launch?

Generic name: semaglutide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 18, 2025
Generic Entry Controlled by: South Korea Patent 101,205,272

Drug Price Trends for WEGOVY
WEGOVY is a drug marketed by Novo. There are six patents protecting this drug.

This drug has one hundred and twenty-two patent family members in thirty-two countries. There has been litigation on patents covering WEGOVY

See drug price trends for WEGOVY.

The generic ingredient in WEGOVY is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.

When can WEGOVY (semaglutide) generic drug versions launch?

Generic name: semaglutide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 18, 2025
Generic Entry Controlled by: South Korea Patent 20,070,120,089
Patent Title: ACYLATED GLP-1 COMPOUNDS

Drug Price Trends for WEGOVY
WEGOVY is a drug marketed by Novo. There are six patents protecting this drug.

This drug has one hundred and twenty-two patent family members in thirty-two countries. There has been litigation on patents covering WEGOVY

See drug price trends for WEGOVY.

The generic ingredient in WEGOVY is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.

When can JATENZO (testosterone undecanoate) generic drug versions launch?

Generic name: testosterone undecanoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 15, 2025
Generic Entry Controlled by: South Korea Patent 101,382,725

Drug Price Trends for JATENZO
JATENZO is a drug marketed by Tolmar. There are ten patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has twenty-nine patent family members in fourteen countries. There has been litigation on patents covering JATENZO

See drug price trends for JATENZO.

The generic ingredient in JATENZO is testosterone undecanoate. There are sixty-nine drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.

When can JATENZO (testosterone undecanoate) generic drug versions launch?

Generic name: testosterone undecanoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 15, 2025
Generic Entry Controlled by: South Korea Patent 101,432,466

Drug Price Trends for JATENZO
JATENZO is a drug marketed by Tolmar. There are ten patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has twenty-nine patent family members in fourteen countries. There has been litigation on patents covering JATENZO

See drug price trends for JATENZO.

The generic ingredient in JATENZO is testosterone undecanoate. There are sixty-nine drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.

When can JATENZO (testosterone undecanoate) generic drug versions launch?

Generic name: testosterone undecanoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 15, 2025
Generic Entry Controlled by: South Korea Patent 20,080,009,201
Patent Title: PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPRISING SAME

Drug Price Trends for JATENZO
JATENZO is a drug marketed by Tolmar. There are ten patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has twenty-nine patent family members in fourteen countries. There has been litigation on patents covering JATENZO

See drug price trends for JATENZO.

The generic ingredient in JATENZO is testosterone undecanoate. There are sixty-nine drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.

When can JATENZO (testosterone undecanoate) generic drug versions launch?

Generic name: testosterone undecanoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 15, 2025
Generic Entry Controlled by: South Korea Patent 20,130,119,518
Patent Title: PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPRISING SAME

Drug Price Trends for JATENZO
JATENZO is a drug marketed by Tolmar. There are ten patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has twenty-nine patent family members in fourteen countries. There has been litigation on patents covering JATENZO

See drug price trends for JATENZO.

The generic ingredient in JATENZO is testosterone undecanoate. There are sixty-nine drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.

When can JATENZO (testosterone undecanoate) generic drug versions launch?

Generic name: testosterone undecanoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 15, 2025
Generic Entry Controlled by: South Korea Patent 20,130,124,414
Patent Title: PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPRISING SAME

Drug Price Trends for JATENZO
JATENZO is a drug marketed by Tolmar. There are ten patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has twenty-nine patent family members in fourteen countries. There has been litigation on patents covering JATENZO

See drug price trends for JATENZO.

The generic ingredient in JATENZO is testosterone undecanoate. There are sixty-nine drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.

When can TYKERB (lapatinib ditosylate) generic drug versions launch?

Generic name: lapatinib ditosylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 19, 2025
Generic Entry Controlled by: South Korea Patent 101,356,748

TYKERB is a drug marketed by Novartis. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty-eight patent family members in twenty-six countries.

See drug price trends for TYKERB.

The generic ingredient in TYKERB is lapatinib ditosylate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the lapatinib ditosylate profile page.

When can TYKERB (lapatinib ditosylate) generic drug versions launch?

Generic name: lapatinib ditosylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 19, 2025
Generic Entry Controlled by: South Korea Patent 20,080,005,557
Patent Title: PHARMACEUTICAL COMPOSITION

TYKERB is a drug marketed by Novartis. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty-eight patent family members in twenty-six countries.

See drug price trends for TYKERB.

The generic ingredient in TYKERB is lapatinib ditosylate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the lapatinib ditosylate profile page.

When can XCOPRI (cenobamate) generic drug versions launch?

Generic name: cenobamate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 22, 2025
Generic Entry Controlled by: South Korea Patent 101,286,499

Drug Price Trends for XCOPRI
XCOPRI is a drug marketed by Sk Life. There are two patents protecting this drug.

This drug has twenty-six patent family members in twenty countries.

See drug price trends for XCOPRI.

The generic ingredient in XCOPRI is cenobamate. One supplier is listed for this generic product. Additional details are available on the cenobamate profile page.

When can XCOPRI (cenobamate) generic drug versions launch?

Generic name: cenobamate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 22, 2025
Generic Entry Controlled by: South Korea Patent 20,080,005,437
Patent Title: NEUROTHERAPEUTIC AZOLE COMPOUNDS

Drug Price Trends for XCOPRI
XCOPRI is a drug marketed by Sk Life. There are two patents protecting this drug.

This drug has twenty-six patent family members in twenty countries.

See drug price trends for XCOPRI.

The generic ingredient in XCOPRI is cenobamate. One supplier is listed for this generic product. Additional details are available on the cenobamate profile page.

When can BELEODAQ (belinostat) generic drug versions launch?

Generic name: belinostat
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 101,329,437

BELEODAQ is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-nine patent family members in twenty-seven countries. There has been litigation on patents covering BELEODAQ

See drug price trends for BELEODAQ.

The generic ingredient in BELEODAQ is belinostat. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the belinostat profile page.

When can BELEODAQ (belinostat) generic drug versions launch?

Generic name: belinostat
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 101,340,824

BELEODAQ is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-nine patent family members in twenty-seven countries. There has been litigation on patents covering BELEODAQ

See drug price trends for BELEODAQ.

The generic ingredient in BELEODAQ is belinostat. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the belinostat profile page.

When can BELEODAQ (belinostat) generic drug versions launch?

Generic name: belinostat
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 20,080,016,636
Patent Title: PHARMACEUTICAL FORMULATIONS OF HDAC INHIBITORS

BELEODAQ is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-nine patent family members in twenty-seven countries. There has been litigation on patents covering BELEODAQ

See drug price trends for BELEODAQ.

The generic ingredient in BELEODAQ is belinostat. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the belinostat profile page.

When can BELEODAQ (belinostat) generic drug versions launch?

Generic name: belinostat
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 20,130,079,665
Patent Title: PHARMACEUTICAL FORMULATIONS OF HDAC INHIBITORS

BELEODAQ is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-nine patent family members in twenty-seven countries. There has been litigation on patents covering BELEODAQ

See drug price trends for BELEODAQ.

The generic ingredient in BELEODAQ is belinostat. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the belinostat profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 101,169,832

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 101,332,889

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 101,332,924

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 101,431,407

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 101,456,722

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 101,515,335

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 101,519,705

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 101,579,701

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 101,600,230

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 101,782,236

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 102,020,721

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 102,324,567

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 102,481,886

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 20,080,014,039
Patent Title: DIARYLHYDANTOIN COMPOUNDS

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 20,090,009,215
Patent Title: DIARYLTHIOHYDANTOIN COMPOUNDS

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 20,110,041,580
Patent Title: DIARYLHYDANTOIN COMPOUNDS

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 20,120,102,140
Patent Title: DIARYLHYDANTOIN COMPOUNDS

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 20,120,102,147
Patent Title: DIARYLTHIOHYDANTOIN COMPOUNDS

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 20,130,060,369
Patent Title: DIARYLHYDANTOIN COMPOUNDS

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 20,140,041,831
Patent Title: DIARYLHYDANTOIN COMPOUNDS

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 20,140,141,676
Patent Title: DIARYLHYDANTOIN COMPOUNDS

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 20,150,008,506
Patent Title: DIARYLTHIOHYDANTOIN COMPOUNDS

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 20,150,086,567
Patent Title: 디아릴히단토인 화합물 (DIARYLHYDANTOIN COMPOUNDS)

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 20,160,027,254
Patent Title: 디아릴티오히단토인 화합물 (DIARYLTHIOHYDANTOIN COMPOUNDS)

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 20,170,107,585
Patent Title: 디아릴히단토인 화합물 (DIARYLHYDANTOIN COMPOUNDS)

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 20,190,104,244
Patent Title: 디아릴히단토인 화합물 (DIARYLHYDANTOIN COMPOUNDS)

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 20,210,136,161
Patent Title: 디아릴히단토인 화합물 (DIARYLHYDANTOIN COMPOUNDS)

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: South Korea Patent 20,230,003,445
Patent Title: 디아릴히단토인 화합물 (DIARYLHYDANTOIN COMPOUNDS)

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can TRACLEER (bosentan) generic drug versions launch?

Generic name: bosentan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 17, 2025
Generic Entry Controlled by: South Korea Patent 20,080,014,002
Patent Title: DISPERSIBLE TABLET

TRACLEER is a drug marketed by Actelion. There are two patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has twenty-eight patent family members in twenty-three countries. There has been litigation on patents covering TRACLEER

See drug price trends for TRACLEER.

The generic ingredient in TRACLEER is bosentan. There are nineteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the bosentan profile page.

When can TRACLEER (bosentan) generic drug versions launch?

Generic name: bosentan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 17, 2025
Generic Entry Controlled by: South Korea Patent 20,100,093,105
Patent Title: DISPERSIBLE TABLET

TRACLEER is a drug marketed by Actelion. There are two patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has twenty-eight patent family members in twenty-three countries. There has been litigation on patents covering TRACLEER

See drug price trends for TRACLEER.

The generic ingredient in TRACLEER is bosentan. There are nineteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the bosentan profile page.

When can LATUDA (lurasidone hydrochloride) generic drug versions launch?

Generic name: lurasidone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 26, 2025
Generic Entry Controlled by: South Korea Patent 101,380,088

Drug Price Trends for LATUDA
LATUDA is a drug marketed by Sunovion Pharms Inc. There are nine patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.

This drug has sixty-nine patent family members in twenty-four countries. There has been litigation on patents covering LATUDA

See drug price trends for LATUDA.

The generic ingredient in LATUDA is lurasidone hydrochloride. There are twenty-six drug master file entries for this API. Twenty-five suppliers are listed for this generic product. Additional details are available on the lurasidone hydrochloride profile page.

When can LATUDA (lurasidone hydrochloride) generic drug versions launch?

Generic name: lurasidone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 26, 2025
Generic Entry Controlled by: South Korea Patent 101,552,033

Drug Price Trends for LATUDA
LATUDA is a drug marketed by Sunovion Pharms Inc. There are nine patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.

This drug has sixty-nine patent family members in twenty-four countries. There has been litigation on patents covering LATUDA

See drug price trends for LATUDA.

The generic ingredient in LATUDA is lurasidone hydrochloride. There are twenty-six drug master file entries for this API. Twenty-five suppliers are listed for this generic product. Additional details are available on the lurasidone hydrochloride profile page.

When can LATUDA (lurasidone hydrochloride) generic drug versions launch?

Generic name: lurasidone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 26, 2025
Generic Entry Controlled by: South Korea Patent 20,080,012,306
Patent Title: PHARMACEUTICAL COMPOSITION

Drug Price Trends for LATUDA
LATUDA is a drug marketed by Sunovion Pharms Inc. There are nine patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.

This drug has sixty-nine patent family members in twenty-four countries. There has been litigation on patents covering LATUDA

See drug price trends for LATUDA.

The generic ingredient in LATUDA is lurasidone hydrochloride. There are twenty-six drug master file entries for this API. Twenty-five suppliers are listed for this generic product. Additional details are available on the lurasidone hydrochloride profile page.

When can LATUDA (lurasidone hydrochloride) generic drug versions launch?

Generic name: lurasidone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 26, 2025
Generic Entry Controlled by: South Korea Patent 20,130,122,019
Patent Title: PHARMACEUTICAL COMPOSITION

Drug Price Trends for LATUDA
LATUDA is a drug marketed by Sunovion Pharms Inc. There are nine patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.

This drug has sixty-nine patent family members in twenty-four countries. There has been litigation on patents covering LATUDA

See drug price trends for LATUDA.

The generic ingredient in LATUDA is lurasidone hydrochloride. There are twenty-six drug master file entries for this API. Twenty-five suppliers are listed for this generic product. Additional details are available on the lurasidone hydrochloride profile page.

When can VICTRELIS (boceprevir) generic drug versions launch?

Generic name: boceprevir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 02, 2025
Generic Entry Controlled by: South Korea Patent 20,080,021,634
Patent Title: PHARMACEUTICAL FORMULATIONS AND METHODS OF TREATMENT USING THE SAME

VICTRELIS is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug.

This drug has one hundred and ten patent family members in thirty-three countries.

The generic ingredient in VICTRELIS is boceprevir. Additional details are available on the boceprevir profile page.

When can APLENZIN (bupropion hydrobromide) generic drug versions launch?

Generic name: bupropion hydrobromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 27, 2025
Generic Entry Controlled by: South Korea Patent 101,306,635

APLENZIN is a drug marketed by Bausch. There are eight patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has fifty-two patent family members in eighteen countries.

See drug price trends for APLENZIN.

The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrobromide profile page.

When can APLENZIN (bupropion hydrobromide) generic drug versions launch?

Generic name: bupropion hydrobromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 27, 2025
Generic Entry Controlled by: South Korea Patent 20,080,026,098
Patent Title: MODIFIED-RELEASE FORMULATIONS OF A BUPROPION SALT

APLENZIN is a drug marketed by Bausch. There are eight patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has fifty-two patent family members in eighteen countries.

See drug price trends for APLENZIN.

The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrobromide profile page.

When can APLENZIN (bupropion hydrobromide) generic drug versions launch?

Generic name: bupropion hydrobromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 27, 2025
Generic Entry Controlled by: South Korea Patent 20,100,055,402
Patent Title: BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS

APLENZIN is a drug marketed by Bausch. There are eight patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has fifty-two patent family members in eighteen countries.

See drug price trends for APLENZIN.

The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrobromide profile page.

When can APLENZIN (bupropion hydrobromide) generic drug versions launch?

Generic name: bupropion hydrobromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 27, 2025
Generic Entry Controlled by: South Korea Patent 20,100,077,182
Patent Title: BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS

APLENZIN is a drug marketed by Bausch. There are eight patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has fifty-two patent family members in eighteen countries.

See drug price trends for APLENZIN.

The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrobromide profile page.

When can BOSULIF (bosutinib monohydrate) generic drug versions launch?

Generic name: bosutinib monohydrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 01, 2025
Generic Entry Controlled by: South Korea Patent 20,080,028,386
Patent Title: CRYSTALLINE FORMS OF 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[3-(4-METHYL-1-PIPERAZINYL)PROPOXY]-3-QUINOLINECARB-ONITRILE AND METHODS OF PREPARING THE SAME

BOSULIF is a drug marketed by Pf Prism Cv. There are five patents protecting this drug and two Paragraph IV challenges.

This drug has eighty-one patent family members in thirty countries. There has been litigation on patents covering BOSULIF

See drug price trends for BOSULIF.

The generic ingredient in BOSULIF is bosutinib monohydrate. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the bosutinib monohydrate profile page.

When can APTIOM (eslicarbazepine acetate) generic drug versions launch?

Generic name: eslicarbazepine acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 29, 2025
Generic Entry Controlled by: South Korea Patent 101,362,281

Drug Price Trends for APTIOM
APTIOM is a drug marketed by Sumitomo Pharma Am. There are eleven patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred patent family members in twenty-six countries. There has been litigation on patents covering APTIOM

See drug price trends for APTIOM.

The generic ingredient in APTIOM is eslicarbazepine acetate. There are twelve drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the eslicarbazepine acetate profile page.

When can APTIOM (eslicarbazepine acetate) generic drug versions launch?

Generic name: eslicarbazepine acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 29, 2025
Generic Entry Controlled by: South Korea Patent 20,080,036,212
Patent Title: ASYMMETRIC CATALYTIC REDUCTION OF OXCARBAZEPINE

Drug Price Trends for APTIOM
APTIOM is a drug marketed by Sumitomo Pharma Am. There are eleven patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred patent family members in twenty-six countries. There has been litigation on patents covering APTIOM

See drug price trends for APTIOM.

The generic ingredient in APTIOM is eslicarbazepine acetate. There are twelve drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the eslicarbazepine acetate profile page.

When can OLYSIO (simeprevir sodium) generic drug versions launch?

Generic name: simeprevir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 29, 2025
Generic Entry Controlled by: South Korea Patent 101,059,419

OLYSIO is a drug marketed by Janssen Prods. There are nine patents protecting this drug.

This drug has one hundred and thirty-nine patent family members in forty-three countries.

See drug price trends for OLYSIO.

The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.

When can OLYSIO (simeprevir sodium) generic drug versions launch?

Generic name: simeprevir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 29, 2025
Generic Entry Controlled by: South Korea Patent 20,080,042,084
Patent Title: MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS

OLYSIO is a drug marketed by Janssen Prods. There are nine patents protecting this drug.

This drug has one hundred and thirty-nine patent family members in forty-three countries.

See drug price trends for OLYSIO.

The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.

When can EPSOLAY (benzoyl peroxide) generic drug versions launch?

Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 02, 2025
Generic Entry Controlled by: South Korea Patent 101,158,162

EPSOLAY is a drug marketed by Galderma Labs Lp. There are nine patents protecting this drug. Two tentatively approved generics are ready to enter the market.

This drug has twenty-eight patent family members in eleven countries.

See drug price trends for EPSOLAY.

The generic ingredient in EPSOLAY is benzoyl peroxide. There are seventeen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the benzoyl peroxide profile page.

When can EPSOLAY (benzoyl peroxide) generic drug versions launch?

Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 02, 2025
Generic Entry Controlled by: South Korea Patent 20,080,039,927
Patent Title: METAL OXIDE COATING OF WATER INSOLUBLE INGREDIENTS

EPSOLAY is a drug marketed by Galderma Labs Lp. There are nine patents protecting this drug. Two tentatively approved generics are ready to enter the market.

This drug has twenty-eight patent family members in eleven countries.

See drug price trends for EPSOLAY.

The generic ingredient in EPSOLAY is benzoyl peroxide. There are seventeen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the benzoyl peroxide profile page.

When can CREON (pancrelipase (amylase;lipase;protease)) generic drug versions launch?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 15, 2025
Generic Entry Controlled by: South Korea Patent 101,302,841

CREON is a drug marketed by

This drug has twenty-eight patent family members in eleven countries. There has been litigation on patents covering CREON

See drug price trends for CREON.

The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can CREON (pancrelipase (amylase;lipase;protease)) generic drug versions launch?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 15, 2025
Generic Entry Controlled by: South Korea Patent 101,344,546

CREON is a drug marketed by

This drug has twenty-eight patent family members in eleven countries. There has been litigation on patents covering CREON

See drug price trends for CREON.

The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can CREON (pancrelipase (amylase;lipase;protease)) generic drug versions launch?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 15, 2025
Generic Entry Controlled by: South Korea Patent 20,080,034,515
Patent Title: CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR ACID LABILE DRUGS

CREON is a drug marketed by

This drug has twenty-eight patent family members in eleven countries. There has been litigation on patents covering CREON

See drug price trends for CREON.

The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can CREON (pancrelipase (amylase;lipase;protease)) generic drug versions launch?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 15, 2025
Generic Entry Controlled by: South Korea Patent 20,080,034,516
Patent Title: PANCREATIN MICROPELLET CORES SUITABLE FOR ENTERIC COATING

CREON is a drug marketed by

This drug has twenty-eight patent family members in eleven countries. There has been litigation on patents covering CREON

See drug price trends for CREON.

The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.